ArticleJournal of pediatric gastroenterology and nutrition2026
Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesAdalimumab is commonly used to induce and maintain remission in pediatric Crohn's disease (CD). However, data on the efficacy and safety of high-dose adalimumab in this population are limited. This study aimed to evaluate the therapeutic effectiveness and safety of weekly high-dose adalimumab (80 mg) in pediatric CD patients.
methodsThis multicenter retrospective study included pediatric patients with CD who received adalimumab 80 mg weekly for more than 30 days following suboptimal response to standard dosing between 2014 and 2023. Clinical and biochemical outcomes, treatment durability, and adverse events (AEs) were assessed at predefined time points. Regression analyses were used to explore predictors of sustained corticosteroid-free remission (SCFR) and clinical response.
resultsThirty-eight patients (71% male; median age 16.3 years [interquartile range, IQR: 14.3-16.9]) underwent dose intensification. Ileocolonic CD was observed in 53%, and 29% had perianal disease. Clinical remission at 12 months was achieved in 50% of patients. Among the 27 patients (71%) with available adalimumab trough concentrations (ATC), 74% reached a therapeutic level (≥7.5 µg/mL) at 1 year. No significant predictors of SCFR or clinical response were identified. Early post-intensification drug levels predicted 12-month remission (AUC = 0.76), with an optimal threshold of 11.3 µg/mL (sensitivity 85%, specificity 67%). Treatment was de-escalated in 5% and discontinued in 26% due to primary nonresponse. AEs occurred in 13%, mainly mild dermatologic reactions.
conclusionsWeekly 80 mg adalimumab appears to be an effective and well-tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.